Search PubMed⌕ Search

Biomedical subjects

Z Wajsman

Publications and source records attributed to Z Wajsman.

126 records · Page 7Linked to original sources
PubMed1976

Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.

There were 33 patients with clinically relapsing advanced prostatic carcinoma (stages C and D) treated by 2 different combinations of chemotherapy. The 13 patients in group 1 received 5-fluorouracil and cyclophosphamide and 20 patients in group 2 received adriamycin and cyclophosphamide. The over-all response was 69.3 per cent in group 1 and 65 per cent in group 2. Our preliminary results should encourage further evaluation of these drug combinations by other investigators under carefully controlled conditions.

Adenocarcinoma↗
PubMed1976

The value of palliative spinal surgery in metastatic urogenital tumors.

There were 22 patients with vertebral metastases and impending neurologic damage from prostatic, vesical and renal cell carcinoma treated by decompressive laminectomy combined with local radiotherapy and chemotherapy. The neurological recovery was complete in the prostatic carcinoma patients (10 of 10), partial in the vesical carcinoma patients (2 of 5) and unsatisfactory in the renal cell carcinoma patients (1 of 7).

Adenocarcinoma↗
PubMed1976

Three hour hemodialysis with double coil dialyzer.

Blood urea nitrogen and weight reduction can be accomplished in renal failure by doubling the surface area of the standard dialysis coils. This results in a reduction of time on the machine, drugs and personnel utilization.

Adolescent↗
PubMed1975

Preliminary reticulum cell sarcoma of prostate gland.

A case of primary reticulum cell sarcoma of the prostate gland is presented. This is the seventh well-documented case we have found in the literature. No evidence of extraprostatic extension has been found two and a half years after diagnosis was made, despite no chemotherapy nor radiotherapy.

Aged↗
PubMed1975

Current results from treatment of bladder tumors with total cystectomy at roswell park memorial institute.

Results of our recent cystectomy series revealed good survival for patients with superficial bladder tumors. The morbidity rate was low, 8.6 per cent. Our series showed a statistically significant postoperative morbidity rate in a high risk patient group, then justifying preoperative selection of patients as condidates for this major operation. However, we believe that despite relatively good results in reducing the morbitidy and mortality rates and improvement in survival, the over-all results in treatment of bladder tumors with operation alone are still unsatisfactory and there is an urgent need to develop and to investigate new and combined modalities of treatment.

Adult↗
PubMed1975

Evaluation of lymphangiography for clinical staging of bladder tumors.

Preoperative lymphangiography was done on 18 patients with bladder cancer and the results were correlated with the surgicopathological findings at the time of radical cystectomy and pelvic lymph node dissection. Correlation between radiological and pathological findings showed no falsely negative results. One patient had a falsely positive interpretation of lymphangiography. The accuracy of the study was 94 per cent. Accurate interpretation of lymphography is related to the experience of the reader. Routine use of lymphangiography in clinical staging of bladder cancer is recommended.

Aged↗
PubMed1975

Evaluation of biological markers in bladder cancer.

The value of biological markers of bladder cancer was studied in 66 patients. The markers included serum and urine carcinoembryonic antigens, serum and urine fibrinogen degradation products, total lymphocyte counts, urine lymphocytes and urine cytology. A high degree of accuracy (90 per cent) was found in correlating cytology and urinary fibrinogen degradation products with the activity of the disease. Serum and urine carcinoembryonic antigens, serum fibrinogen degradation products, total lymphocyte counts and urine lymphocytes were found to have no value in screening bladder cancer patients. Urinary fibrinogen degradation products and cytology in combination are recommended for screening and followup of patients at high risk.

Carcinoembryonic Antigen↗
PubMed1975

Chemotherapy of bladder carcinoma with cyclophosphamide and adriamycin.

We assigned 49 patients with transitional cell carcinoma of the bladder to 1 of 3 groups: 21 patients (group 1) received cyclophosphamide alone, 10 patients (group 2) received adriamycin alone and 18 patients (group 3) received cyclophosphamide and adriamycin. The objective responses were 52.3 per cent in group 1, 10 per cent in group 2 and 50 per cent in group 3. These results suggest a significant activity of the drugs (especially in groups 1 and 3) tested in bladder cancer.

Aged↗
PubMed1972

[Rectal atresia].

Explore the source record for details and available documents.

Abnormalities, Multiple↗
PubMedDate not supplied

Bladder-sparing treatment of invasive bladder cancer.

BACKGROUND: Radical cystectomy with pelvic lymph node dissection is the standard treatment for patients with invasive bladder cancer. However, many alternative techniques to spare the bladder have been investigated. METHODS: We review the experience reported in the literature on bladder-sparing techniques, including transurethral resection, chemotherapy, and radiation for muscle-invasive disease. RESULTS: Most comparative studies indicate that local recurrence and survival outcomes for bladder-sparing approaches are inferior to those from radical cystectomy to control muscle-invasive bladder cancer. CONCLUSIONS: Although molecular biologic techniques may have the capacity to identify a subgroup who may benefit from a bladder-sparing approach, cystectomy is normally required for optimal results.

Antineoplastic Agents↗
PubMedDate not supplied

Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin.

Seventeen patients with histologically proven adenocarcinoma of the prostate were selected for evaluation of their immunologic competence and therapy with bacillus Calmette-Guérin (BCG). All patients were in stage D. The immune response was explored in two main aspects: cell-mediated and humoral immunity. Delayed skin hypersensitivity reaction with purified protein derivative (PPD), streptokinase-streptodornase (varidase), Candida, mumps antigen, and Trichophyton were tested. Lymphocyte reactivity was measured by in vitro blastogenesis. Serum immunoglobulin levels and serum protein electrophoresis were also measured. The patients were then divided in two groups according to the skin test response to PPD. Group 1 (PPD-positive) consisted of seven patients. Group 2 (PPD-negative) consisted of ten patients. In group 1, two patients were treated with intraprostatic injection of BCG every week in the following doses: 1 cc the first week, 2 cc the second week, 4 cc the third week, and 6 cc the fourth week. The five remaining patients in this group received only 1 cc every week for 4 weeks. The group 2 patients (PPD-negative) were stimulated by oral intake of BCG in an attempt to convert their skin tests to positive. All patients revealed varying degrees of immunodepression. None of the patients in group 2 (stimulated by oral intake of BCG) converted to positive skin tests. Three patients in group 1 treated with BCG showed necrosis of the tumor. The different aspects of immunodepression in this disease are analyzed and correlated to the clinical staging, histologic grading, and response to therapy. The mechanism of BCG action in advanced prostatic carcinoma is discussed.

Adenocarcinoma↗